Dr. Richard Y. Zhao is a tenured Professor in the Department of Pathology and Microbiology-Immunology at the University of Maryland School of Medicine. His research combines molecular biology, fission yeast genetics, mammalian biology, and virology to study virus-host interactions, particularly for HIV and Zika virus. He previously held academic positions at Northwestern University and Columbia University and has contributed to over 120 peer-reviewed articles. B.S., China Oceanography University (1981) M.S., Oregon State University (1995) Ph.D., Oregon State University (1991) Postdoctoral Training, Columbia University (1991-1992) Dr. Zhao's research focuses on: Virus-host interactions and pathogenicity High-throughput drug screening for antivirals Role of viral proteins in neuroinflammation and cancer Translational genomics in precision medicine His recent publications highlight SARS-CoV-2 ORF3a, Zika envelope proteins, and HIV protease inhibitors, emphasizing host-pathogen mechanisms across species. He has served on NIH panels and editorial boards for journals like Cell Research and Retrovirology . Scientific awards include: Fellow, American Academy of Microbiology (2019) Bernard L Mirkin Endowed Chair (2001-2004) Honorary Director, Shandong Gallo Institute (2009) Distinguished Service from SCBA (2015) Outstanding Service from CBA-USA (2016) Dr. Zhao also contributes to clinical diagnostics and personalized medicine through molecular testing and pharmacogenetics programs.
Professor Dario Alessi is a leading academic at the University of Dundee's School of Life Sciences, serving as the Director of the MRC Protein Phosphorylation Unit (MRC PPU) and Professor of Signal Transduction. He earned his BSc (1988) and PhD (1991) from the University of Birmingham. His research focuses on protein phosphorylation and ubiquitylation pathways, particularly the LRRK2 kinase pathway linked to Parkinson's disease. He has made groundbreaking contributions to understanding LRRK2's role in neurodegeneration, including its interaction with Rab proteins and scaffolding molecules like RILPL1. School of Life Sciences, University of Dundee MRC PPU Director since 2012 Signal Transduction Therapy Unit Director His work combines molecular biology, biochemistry, and collaborative industry partnerships to advance therapeutic strategies for Parkinson's disease. Key research areas include LRRK2 activation mechanisms, Rab protein phosphorylation, and lysosomal dysfunction. Alessi has trained over 30 graduate students and 40 postdocs, many now in academic and industry leadership roles. Notable awards include the EMBO Gold Medal (2005), the Robert A. Pritzker Prize for Leadership in Parkinson’s Research (2023), and an OBE (2023) for contributions to medical science. His lab promotes open science, sharing reagents and protocols globally through platforms like MRC Pure Agents and LRRK2.bio. Current projects include investigating novel mitochondrial and organelle biology in Parkinson’s, developing biomarkers, and advancing LRRK2 inhibitors through clinical trials. Collaborations span the Michael J. Fox Foundation, Aligning Science Across Parkinson’s, and the UK Dementia Research Initiative.
Pierre Maechler is a Professor at the University of Geneva's Faculty of Medicine in the Department of Cell Physiology and Metabolism. His research focuses on mitochondrial metabolism in pancreatic beta cells and its critical role in diabetes pathogenesis, with particular emphasis on glutamate dehydrogenase function and regulation. His laboratory investigates the molecular mechanisms of insulin secretion and beta-cell failure in Type 2 diabetes. Maechler's research interests span mitochondrial metabolism, energy homeostasis, and the molecular pathways linking nutrient sensing to insulin secretion. His work has established crucial connections between glutamate metabolism, beta-cell function, and diabetes development. He investigates how metabolic stressors like glucotoxicity and lipotoxicity impair beta-cell function through mitochondrial dysfunction. His research has expanded to include the role of glutamate dehydrogenase in multiple organs including brain, liver, and muscle, revealing systemic metabolic implications. Analysis of Maechler's publication record shows a sustained focus on beta-cell metabolism with evolving scope. Early work established fundamental mechanisms of glutamate signaling in insulin secretion, while recent publications demonstrate expansion into multi-organ metabolic regulation. His research has identified novel biomarkers for beta-cell mass, explored therapeutic targets for diabetes, and revealed unexpected roles for glutamate dehydrogenase in diverse physiological processes from muscle regeneration to brain function. The consistent thread through his work is understanding how mitochondrial metabolism governs cellular and systemic energy homeostasis. Professor Maechler has mentored numerous PhD students and postdoctoral fellows who have gone on to publish significant work in diabetes research. His laboratory collaborates extensively with clinical researchers to translate basic findings into potential therapeutic approaches for diabetes. Funding for his work likely comes from Swiss National Science Foundation and other European research agencies, supporting investigations into metabolic diseases. Maechler leads the Mitochondria and Energy Metabolism research group at the University of Geneva. His team employs a multidisciplinary approach combining molecular biology, metabolomics, and physiology to investigate metabolic regulation in health and disease. The laboratory maintains strong connections with clinical diabetes researchers, facilitating translational applications of their findings. Current work focuses on identifying novel therapeutic targets for preserving beta-cell function in diabetes.
Karen Bandeen-Roche is a Professor and the Hurley-Dorrier Professor and Chair of the Department of Biostatistics at the Johns Hopkins Bloomberg School of Public Health, with joint affiliations in the School of Medicine and the School of Nursing. She is a leading expert in biostatistical methodology, particularly in latent variable models, longitudinal analysis, and multivariate survival methods applied to aging and gerontology. Her research focuses on developing statistical models for unobservable processes such as frailty, resilience, and functional status in older adults. She has made significant contributions to the measurement of aging-related constructs and has extensive collaborative work in ophthalmology and neurology. Her methodological work includes mixture models, measurement error correction, and latent class modeling. The recent publications highlight a strong trend in gerontological biostatistics, with a focus on frailty, dementia risk, resilience, and multisystem physiological responses in aging. Her work integrates complex data from observational cohorts and clinical studies, often employing innovative latent variable frameworks to address measurement challenges in health outcomes. Scientific Awards and Honors: Marvin Zelen Leadership Award in Statistical Science (2016) Fellow of the American Statistical Association (2001) Brookdale National Fellow (1997) Golden Apple Award for Excellence in Teaching (2010) Garland Clay Award (1999) Chair, NIH BMRD Study Section (2006–2008) President, Eastern North American Region, International Biometric Society (2011–2013) Executive Board, International Biometric Society (2015–2022) Board of Directors, National Institute of Statistical Sciences (2020–2023) Karen Bandeen-Roche has been deeply involved in advising and training the next generation of researchers. She co-directs a training program in Biostatistics and Epidemiology of Aging and has received multiple teaching and mentoring awards. She has served on numerous academic committees, including appointments and promotions, faculty senate, and ethics committees at Johns Hopkins. Her grants and collaborative research span aging, dementia, ophthalmology, and cardiovascular health, often supported by NIH and other federal agencies. She leads the Center on Aging and Health and is actively involved in interdisciplinary research initiatives that bridge biostatistics, medicine, and public health. Her lab and research team focus on developing and applying advanced statistical methods to understand the biological and social determinants of healthy aging.
Pilar Pérez Romero is an Associate Professor in the Department of Biological Sciences at the University of Notre Dame, where she leads research on human cytomegalovirus (CMV) and host immune interactions. She has previously held academic positions at the National Centre for Microbiology in Madrid and the Biomedical Institute of Seville, Spain. Her research interests include: Virology and molecular mechanisms of CMV infection Virus-host interactions and immune evasion CMV-specific T-cell and neutralizing antibody responses Immunotherapy and vaccine design for CMV Applications in solid organ transplant recipients and congenital infection Her recent publications show a strong focus on CMV immunopathogenesis, with increasing emphasis on translational applications such as monoclonal antibody therapies, adoptive T-cell transfer, and vaccine development. She frequently employs transcriptomic and proteomic methods and collaborates on clinical studies involving transplant patients. Her scientific contributions include: Characterization of CMV antigens inducing protective immunity Identification of novel viral gene products involved in immune regulation Development of methods for CMV gene deletion and functional studies Contributions to clinical guidelines for CMV management in transplantation Dr. Pérez Romero advises research students and collaborates with multidisciplinary teams, including immunologists, virologists, and clinicians. Her work is supported by institutional and collaborative research funding, with potential applications in antiviral therapies and vaccinology. She leads a research laboratory focused on viral immunology and pathogenesis at Notre Dame.
Andrew de Mello serves as Full Professor and Deputy Head at ETH Zurich's Department of Chemistry and Applied Biosciences, where he also leads the Institute of Chemical and Bioengineering. His research group operates at the intersection of microfluidics and nanoscale science, maintaining a highly international team with members from over 15 countries. The deMello Group specializes in microfluidic device development for high-throughput biological analysis, ultrasensitive optical detection , nanofluidic chemical synthesis systems , and imaging flow cytometry . Their work spans analytical chemistry, biomedical engineering, and diagnostic applications, with recent projects focusing on paper-based electrofluidic devices, synthetic gene circuits for tuberculosis detection, and droplet-based microfluidics for mRNA screening. Professor de Mello's scholarly contributions include over 350 peer-reviewed publications and two co-authored books. His editorial leadership includes serving as Associate Editor for ACS Sensors and on editorial boards for Advanced Materials Technologies, Chem, and Chemistry World. Advances in Measurement Science Lectureship (ACS, 2020) Qinghe Lectureship (Chinese Academy of Sciences, 2018) Corday-Morgan Medal (RSC, 2009) Clifford Paterson Medal (Royal Society, 2009) SAC Silver Medal (RSC, 2002) His research group actively mentors doctoral students across diverse projects including microrobot fabrication, tumor spheroid vascularization, and spatial tissue mapping. Current grants support development of diagnostic platforms for kidney function monitoring and drug-resistant tuberculosis detection, with collaborations spanning ETH Zurich, Universitätsspital Zürich, and international institutions.
Arjun (Raj) Manrai is an Assistant Professor at Harvard Medical School and a faculty member in the Computational Health Informatics Program (CHIP) at Boston Children’s Hospital. He earned an A.B. in Physics (Harvard, Highest Honors) and a Ph.D. in Bioinformatics and Integrative Genomics from Harvard-MIT. His research focuses on improving medical decision-making through computational approaches in clinical genomics, algorithmic bias mitigation, and healthcare AI ethics. Key projects include race-free kidney function equations, genetic variant classification, and semi-supervised learning for medical imaging. Education: B.A. in Physics, Harvard University (Highest Honors) Ph.D. in Bioinformatics and Integrative Genomics, Harvard-MIT Division of Health Sciences and Technology Research interests span AI-driven diagnostics, health equity, and reproducibility in biomedical studies. His work has been featured in New England Journal of Medicine , JAMA , and highlighted by the New York Times and NPR. Notable contributions include advancing race-free diagnostic algorithms, addressing biases in clinical genomics, and advocating for transparent AI systems in healthcare. The Manrai Lab collaborates widely to translate computational methods into clinical practice.
Cheryl Walker, Ph.D., is a Professor in the Departments of Molecular and Cellular Biology, Medicine, and Molecular and Human Genetics at Baylor College of Medicine. She serves as Director of the Center for Precision Environmental Health and Co-Leader of the Chromatin Biology Program at the Dan L Duncan Comprehensive Cancer Center. Her research focuses on gene-environment interactions, epigenomics, and the molecular mechanisms underlying diseases such as cancer, fibroids, and non-alcoholic fatty liver disease (NAFLD). Key areas include the role of chromatin remodelers like SETD2 in genomic stability and their dual functions in cytoskeletal dynamics. She has pioneered studies on how early-life environmental exposures, such as endocrine-disrupting chemicals (EDCs), reprogram the epigenome to increase disease susceptibility later in life. Dr. Walker’s work is funded by NIH and DOD grants, including leadership of the TaRGET II Consortium for environmental epigenomics. Her lab employs cutting-edge technologies like ChIP-seq and RNA-seq to study epigenetic reprogramming. Notable contributions include discoveries linking SETD2 methylation to microtubule stability and genomic integrity, and identifying epigenetic signatures of environmental exposures in health disparities research. Education: Ph.D. in Molecular Biology Affiliations: Baylor College of Medicine, Gulf Coast Center for Precision Environmental Health Her awards include election to the National Academy of Medicine and fellowships in the American Association for the Advancement of Science (AAAS) and American Thoracic Society (ATS). The lab actively collaborates on translational projects, including biomarker development and disaster-related health studies following events like Hurricane Harvey. Key Research Themes: Epigenetic drivers of cancer and fibrosis Environmental epigenomics and disease risk Chromatin-cytoskeleton cross-talk in disease
Bin Nan serves as Chancellor's Professor in the Department of Statistics at the University of California, Irvine, where he develops statistical and machine learning methodologies to advance biomedical research and improve human health outcomes through rigorous data analysis. His educational credentials demonstrate a strong quantitative foundation: Ph.D. in Biostatistics, University of Washington (2001) M.S. in Biostatistics, University of Washington (1999) M.S. in Statistics, Virginia Commonwealth University (1997) M.S. in Aerospace Engineering, Beijing University of Aeronautics & Astronautics (1987) B.S. in Aerospace Engineering, Beijing University of Aeronautics & Astronautics (1984) Nan's research program focuses on developing cutting-edge statistical methods for survival analysis, longitudinal data, high-dimensional inference, and machine learning, with direct applications to epidemiology, bioinformatics, and brain imaging. His work addresses critical challenges in biomedical data such as temporal dependence in neuroimaging sequences, estimation of large correlation matrices, and analysis of disease onset with terminal events, all aimed at identifying biomarkers for earlier disease diagnosis. Analysis of his recent publications (2015-2023) reveals a consistent trajectory toward methodological innovation in handling complex biomedical data structures, particularly through de-biased lasso techniques for survival models, neural network applications to censored data, and specialized approaches for longitudinal data with terminal events. These advances predominantly support Alzheimer's disease research and transplant outcome studies. No specific scientific awards were documented in the source material. His research program maintains continuous funding through National Science Foundation and National Institutes of Health grants, including a recent $1.8 million award for Alzheimer's disease methodology development. Nan actively collaborates with the UCI Alzheimer's Disease Research Center and UCI Center for the Neurobiology of Learning and Memory, though student advising details were not provided. His teaching portfolio includes advanced graduate courses in probability theory, survival analysis, and high-dimensional inference. Nan operates within interdisciplinary biomedical research teams focused on translating statistical innovation into clinical applications, particularly through brain imaging analysis and biomarker identification for neurodegenerative diseases.
Daniel B. Vigneron, PhD is a Professor at the University of California, San Francisco (UCSF) Department of Radiology and Biomedical Imaging. He serves as Director of the Hyperpolarized MRI Technology Resource Center (HMTRC), Director of Human Imaging Core Services, Director of Advanced Imaging Technologies SRG, and Operations Director of the Surbeck Laboratory for Advanced Imaging. As a core member of the UCB/UCSF Graduate Group in Bioengineering, Vigneron has established himself as a leader in molecular imaging research with over three decades of experience at UCSF. Vigneron's research focuses on developing advanced functional and metabolic MRI techniques, particularly hyperpolarized carbon-13 technology, for studying prostate cancer, brain tumors, and other diseases. His work enables non-invasive imaging of metabolic processes, allowing clinicians to monitor therapy effectiveness and guide treatments. The HMTRC, which he founded in 2011 with NIH funding and recently secured a 5-year renewal for, has supported 20 external projects domestically and 15 internationally, produced 239 publications, and trained 149 researchers. Vigneron's lab develops novel coil and software techniques for high-field MRI, MR spectroscopy, and diffusion imaging at 3T and 7T for studying brain, prostate cancer, and other organs. His recent publications demonstrate a clear trajectory toward clinical translation of hyperpolarized carbon-13 MRI across multiple organ systems. The research spans abdominal imaging with advanced denoising techniques, cardiac metabolism studies, whole-brain coverage applications, and cerebral perfusion analysis. This work represents a significant shift from basic science toward practical clinical applications in oncology, cardiology, and neurology, with particular emphasis on standardization for multi-center studies. Scientific Awards: 2022 Outstanding Faculty Mentoring Award from UCSF Department of Radiology and Biomedical Imaging Vigneron has mentored 149 trainees throughout his career, with several former students now serving as faculty members including Duan Xu, Peder Larson, and Susan Noworolski. As Principal Investigator overseeing eight grants, he has secured significant NIH funding for the HMTRC and other research initiatives. His administrative leadership extends to co-chairing the department's Safety and Compliance Committee, where he has helped establish robust safety protocols for PET-MR programs. Vigneron's mentoring philosophy emphasizes adapting to individual needs at different career stages, moving from instructor to coach to manager to cheerleader as trainees progress. The Vigneron Lab, located in Byers Hall on the UCSF Mission Bay campus, operates within the Surbeck Laboratory for Advanced Imaging. The lab group develops novel acquisition techniques and hardware for multinuclear MR spectroscopy, with particular focus on hyperpolarized carbon-13 metabolic imaging. The HMTRC serves as a hub for team science, bringing together researchers from diverse disciplines to advance metabolic imaging technology and its clinical applications.
Ben Allen is an Associate Professor in the Department of Cell and Developmental Biology at the University of Michigan. His research focuses on the mechanisms of growth factor and morphogen signaling, particularly Hedgehog (HH) signaling in development, tissue homeostasis, and cancer. Employing techniques such as mouse genetics, chicken in ovo electroporations, and biochemical analyses, his lab investigates HH signaling regulation in embryonic/postnatal development and diseases like pancreatic cancer. Recent work explores HH pathway roles in taste organ repair, kidney morphogenesis, and immunosuppressive tumor microenvironments. The lab's publications highlight interdisciplinary approaches, with keywords spanning developmental biology, cancer biology, and signal transduction. Subfields include pancreatic cancer progression, ciliary transport, GLI transcription factor dynamics, and tissue-specific signaling modulation. Collaborations with cancer researchers and regenerative medicine specialists are evident. Allen's group also contributes to science education initiatives, exemplified by their "Developing Future Biologists" program targeting underrepresented undergraduate students.
Bjørn Olav Åsvold, MD, PhD, is a Professor of Medicine (Epidemiology) and Center leader at the HUNT Centre for Molecular and Clinical Epidemiology (HUNT MCE), Department of Public Health and Nursing, Norwegian University of Science and Technology (NTNU). He also serves as a Consultant at the Department of Endocrinology, St. Olavs Hospital, Trondheim University Hospital. His research spans epidemiology, genetics, and clinical medicine. MD, Norwegian University of Science and Technology, 2001 PhD, Norwegian University of Science and Technology, 2008 Specialist in internal medicine, 2014 Specialist in endocrinology, 2015 Åsvold's research focuses on thyroid dysfunction and diabetes , investigating their interplay with cardiometabolic diseases and pregnancy complications . He utilizes Mendelian randomization studies to explore causal relationships between genetic factors and health outcomes, including sleep traits , autoimmune thyroid disease , and kidney function . His work also addresses global health issues like obesity in Nepal and diabetic complications in Norway. Recent publications highlight his contributions to understanding hip fracture risk prediction , cardiovascular implications of sleep patterns , and genetic determinants of trace elements . Åsvold's collaborations span multiple international institutions, including the HUNT Study and HUNT MCE in Norway.
Alex V. Levin, M.D., M.H.Sc., serves as Professor in the Department of Ophthalmology at the University of Rochester School of Medicine and Dentistry, holding the Adeline Lutz - Steven S.T. Ching, M.D. Distinguished Professorship. He concurrently holds joint appointments in the Center for Visual Science and the Department of Pediatrics, Genetics. As Chief of the Flaum Eye Institute's Pediatric Ophthalmology and Ocular Genetics team and Chief of Clinical Genetics at URMC, he leads cross-functional teams comprising ophthalmologists, optometrists, pediatric specialists, geneticists, nurses, and genetic counselors. Medical Degree: Jefferson Medical College Residency: Pediatrics at Children's Hospital of Philadelphia Residency: Ophthalmology at Wills Eye Hospital Fellowship: Pediatric Ophthalmology and Strabismus at Toronto's Hospital for Sick Children Masters of Health Science in Bioethics: University of Toronto (2001) Dr. Levin's research spans ocular genetics and gene therapy, children's vision screening, pediatric glaucoma/cataract/uveitis, ocular manifestations of child abuse, and bioethics. His work integrates clinical expertise in pediatric anterior segment eye conditions with scientific investigation into genetic eye diseases. He maintains the only simultaneous US Board Certifications in pediatrics, ophthalmology, and child abuse pediatrics worldwide. Analysis of his 15 most recent publications reveals predominant focus on genetic eye disorders (73%), with significant emphasis on retinal hemorrhage patterns in trauma (13%) and pediatric glaucoma (7%). His research demonstrates consistent translational application from basic science to clinical practice, particularly in ocular genetics and abusive head trauma diagnostics. Resident Guardian Award (2022) Edward A. Jaeger and John B. Jeffers Citizenship Award (2020) Albert Marquis Lifetime Achievement Award (2018) Al Biglan Medal in Pediatric Ophthalmology (2014) Ray E. Helfer Society Award for Child Abuse Research (2011) With over 35 years of experience and hundreds of peer-reviewed publications, Dr. Levin has secured funding from the National Institutes of Health, Canadian Institute of Health, and private foundations. His research portfolio demonstrates exceptional continuity in pediatric ophthalmology and ocular genetics, with recent emphasis on deep learning applications for retinal hemorrhage analysis and international registry development for childhood glaucoma. He has established comprehensive vision screening programs for underserved urban populations and pioneered ethical frameworks for genetic testing in pediatric ophthalmology. Dr. Levin directs the Ocular Genetics Program at URMC, which provides multidisciplinary care through the Pediatric Ophthalmology and Ocular Genetics team. His laboratory investigations focus on nascent chromatin structure in fibrosis and protein modeling for inherited retinal diseases, with active collaborations across the Montalcino Aortic Consortium and Sturge-Weber Foundation research networks.
Olga G. Troyanskaya is a Professor of Computer Science and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. She serves as Deputy Director for Genomics at the Simons Center for Data Analysis, Simons Foundation, NYC. Her research focuses on computational biology, integrating diverse high-throughput genomic datasets to model molecular pathways in health and disease. Professor of Computer Science and Lewis-Sigler Institute for Integrative Genomics Deputy Director for Genomics, Simons Center for Data Analysis Research Interests: Troyanskaya’s work addresses challenges in bioinformatics, including algorithm development for gene expression analysis, regulatory network modeling, and disease mechanism interpretation. She combines computational methods with experimental validation using S. cerevisiae as a model organism. Scientific Trends: Recent publications emphasize single-cell multiomics, deep learning for transcriptional regulation, cancer immunotherapy design, and epigenomic analysis of immune responses. Key themes include computational modeling of genetic networks, disease-specific pathway analysis, and high-resolution omics frameworks. Collaborative roles in autism, Alzheimer’s, kidney disease, and cancer research Developed tools like HumanBase for data-driven predictions
Professor Maria Eriksdotter is a leading academic in geriatrics and dementia research at the Karolinska Institutet , holding the Department of Neurobiology, Care Sciences and Society . She also serves as a Senior Consultant in Themes Inflammation and Ageing at Karolinska University Hospital Huddinge and previously as Dean of KI South (2019–2023). Her work spans translational research, clinical trials, and national registry development, with a focus on Alzheimer's disease, cholinergic therapies, and aging. Her research group pioneered NGF cell therapy for Alzheimer's patients, demonstrating safety and cognitive stabilization in clinical trials. She chairs the SveDem registry , tracking over 100,000 dementia patients to refine diagnostics and care. Studies from SveDem revealed mortality reduction with cholinesterase inhibitors and highlighted pandemic-era diagnostic delays. Recent publications analyze dementia subtypes , comorbidities , and precision medicine in neurodegeneration. Her work intersects neuroimaging , epidemiology , and public health policy , addressing ageism and improving geriatric care systems. Collaborations span Karolinska University Hospital , NSGene Inc , and international institutions.
